Lantheus (NASDAQ:LNTH) PT Raised to $100.00 at Mizuho

Lantheus (NASDAQ:LNTH) had its price objective upped by analysts at Mizuho from $90.00 to $100.00 in a report issued on Friday, Benzinga reports. The firm currently has a “buy” rating on the medical equipment provider’s stock. Mizuho’s price objective would indicate a potential upside of 32.40% from the company’s current price.

LNTH has been the topic of several other reports. B. Riley lifted their price target on Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. Truist Financial reaffirmed a “buy” rating and set a $82.00 price objective (up previously from $80.00) on shares of Lantheus in a research report on Monday, February 26th. JMP Securities reissued a “market outperform” rating and set a $100.00 target price on shares of Lantheus in a research report on Friday, February 23rd. Finally, StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Lantheus has a consensus rating of “Moderate Buy” and an average target price of $103.14.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $75.53 on Friday. The business’s 50-day simple moving average is $62.67 and its 200-day simple moving average is $62.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 5.45 and a current ratio of 4.84. Lantheus has a 52 week low of $50.20 and a 52 week high of $100.85. The firm has a market cap of $5.18 billion, a price-to-earnings ratio of 11.53 and a beta of 0.52.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, beating the consensus estimate of $1.33 by $0.26. The company had revenue of $354.00 million for the quarter, compared to the consensus estimate of $350.44 million. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. As a group, equities research analysts expect that Lantheus will post 5.96 earnings per share for the current fiscal year.

Insider Transactions at Lantheus

In related news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was acquired at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the transaction, the insider now directly owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of Lantheus stock in a transaction on Wednesday, March 6th. The shares were purchased at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the transaction, the insider now directly owns 116,773,394 shares in the company, valued at $110,934,724.30. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the sale, the director now directly owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The disclosure for this sale can be found here. In the last ninety days, insiders sold 94,545 shares of company stock valued at $6,169,936. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Lantheus

Institutional investors and hedge funds have recently bought and sold shares of the business. Tucker Asset Management LLC raised its holdings in shares of Lantheus by 239.0% in the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 282 shares during the last quarter. UMB Bank n.a. increased its holdings in shares of Lantheus by 161.4% in the first quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 247 shares in the last quarter. First Horizon Advisors Inc. raised its position in Lantheus by 97.0% in the 3rd quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 225 shares during the last quarter. Principal Securities Inc. acquired a new position in Lantheus during the 4th quarter worth $28,000. Finally, Covestor Ltd boosted its position in Lantheus by 62.7% in the 3rd quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 203 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.